✦ LIBER ✦

Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients

✍ Scribed by Rubinstein, A.; Wasserman, R.L.; Melamed, I.; Stein, M.; McCoy, B.; Engl, W.; Leibl, H.; Gelmont, D.; Schiff, R.I.; Grossman, W.J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tolerability of Human Immunoglobulin 10%

✍ Gelmont, D.; Wasserman, R.L.; Melamed, I.; Stein, M.; Rubinstein, A.; McCoy, B.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Pharmacokinetics (PK) of Human Immunoglo

✍ Stein, M.; Wasserman, R.L.; Melamed, I.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Pharmacokinetic Analysis (PK) of Immune

✍ Leibl, H.; Wasserman, R.L.; Melamed, I.; Stein, M.; Engl, W.; Schiff, R.I.; Gelm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Safety and Pharmacokinetics of Facilitat

✍ Melamed, I.; Wasserman, R.L.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Tolerability and Efficacy of Facilitated

✍ Wasserman, R.L.; Melamed, I.; Stein, M.; Puck, J.; Gupta, S.; Engl, W.; Leibl, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 41 KB